Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AKTive-001
NCT06533059Phase 1Active, not recruiting
- Sponsor
- Alterome Therapeutics
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label, single-arm trial of tanerasertib in solid tumor, sponsored by Alterome Therapeutics. Primary endpoints: Adverse Events at 39 months and Dose Limiting Toxicities at 21 days. Started Aug 2024; status: active, not recruiting.
02
Drugs
tanerasertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06533059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06533059.